Dermapharm Holding SE
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
33.24%
Market Cap
2.40 Bil.
P/E Ratio
16.00
Dividend Yield
2.24 %
Earnings per Share
2.46 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 48.45 G | 0 Units |
| PRICE DETERMINATION TIME | 06/03/2026 / 09:55:46 PM | |
| DAILY VOLUME (UNITS) | 876 | |
| DAILY HIGH / LOW | 48.95 | 46.7 |
| PREV. DAY'S PRICE | 46.7 | (06/02) |
| CHANGE DAY BEFORE | +1.75 | 3.75 % |
| 52 WEEK HIGH / LOW | 51.5 (05/18) | 31.8 (08/07) |
Key Figures (in EUR)
| 2027e | 2026e | 2025 | 2024 | 2023 | |
|---|---|---|---|---|---|
| EARNINGS PER SHARE | 2.91 | 2.63 | 2.46 | 2.11 | 1.16 |
| DIVIDENDS PER SHARE | 1.05 | 0.99 | 0.88 | 0.90 | 0.88 |
| DIVIDEND YIELD IN % | - | - | 2.24 % | 2.31 % | 2.08 % |
| DIVIDEND GROWTH IN % | - | - | -2.22 % | 2.27 % | -16.19 % |
| PRICE - EARNINGS RATIO | 16.74 | 18.51 | 16.00 | 18.41 | 36.55 |
| PRICE - BOOK RATIO | - | - | 3.05 | 3.47 | 4.23 |
| PRICE - SALES RATIO | - | - | 1.82 | 1.77 | 2.01 |
| PRICE - CASH FLOW RATIO | - | - | 11.67 | 13.76 | 11.93 |
Master Data
| WKN | A2GS5D |
| ISIN | DE000A2GS5D8 |
| SYMBOL | DMP |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | DERMAPHARM HLDG INH O.N. |
| INDEX MEMBERSHIP | SDAX |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 49.54 Mil. |
| MARKET CAPITALISATION | 2.40 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -2.30 % | 1.30 % | 18.53 % | 26.05 % | 33.24 % | -1.85 % | -32.51 % | 19.44 % |
| HIGH | 49.45 | 51.50 | 51.50 | 51.50 | 51.50 | 51.50 | 91.95 | 51.50 |
| LOW | 46.65 | 45.65 | 36.90 | 34.25 | 31.80 | 29.80 | 29.80 | 34.25 |
Dividend
per share
Company profile
Dermapharm Holding SE engages in the development, manufacture, and marketing of patent-free pharmaceutical products. It operates through the Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts divisions. Its product covers prescription pharmaceuticals (Rx), over-the-counter (OTC) products, medical devices, food supplements, and cosmetics. The company was founded in 1991 and is headquartered in Grunwald, Germany.
Structured products for Dermapharm Holding SE
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 23 days)
06/26/26Annual General Meeting
(in 83 days)
08/25/26Q2 2026 Earnings Release
(in 162 days)
11/12/26Q3 2026 Earnings Release
(in 315 days)
04/14/27Q4 2026 Earnings Release
(in 350 days)
05/19/27Q1 2027 Earnings Release